Recombinant alpha-2b-interferon dynamic test as a potential tool in predicting disease status during second look in ovarian cancer: A preliminary report

G. Scambia, P. B. Panici, G. Baiocchi, A. Gallo, G. Laurelli, S. Iacobelli, S. Mancuso

Research output: Contribution to journalArticle

Abstract

The circulating levels of a 90-kilodalton (KD) tumor-associated antigen were measured in the blood of 26 patients with ovarian cancer in clinical remission who received a short course of recombinant alpha-2b-interferon (rIFN-alpha-2b, 3 million U/m2/d intramuscularly for 3 days) before second- look procedures. The administration of rIFN-alpha-2b to 90-KD antigen- positive patients produced a slight increase of the marker. However, in patients without the marker but with evidence of disease, a remarkable increase above the cutoff level was observed. Less pronounced modifications of 90-KD antigen serum levels were found in patients with no disease at second look. Moreover, considering the 90-KD antigen mean percentage increase, the dynamic test with rIFN-alpha-2b was able to eliminate five of six false-negative results obtained with the 90-KD antigen basal assay alone. The sensitivity of the assay increased to 92% after IFN compared with 54% for the 90-KD antigen assay alone. An increase (> 100% above pretreatment titer) of 90-KD antigen levels during the test also was observed in four patients with no evidence of disease at second look. In two of these false-positive cases, recurrence of disease was observed 13 and 24 months later. At the time of this analysis, none of the patients with a negative second look and negative dynamic test had relapsed. These results suggest that the dynamic test with rIFN-alpha-2b might be a new tool to assess disease status in patients with ovarian cancer before second-look procedures.

Original languageEnglish
Pages (from-to)2582-2585
Number of pages4
JournalCancer
Volume68
Issue number12
Publication statusPublished - 1991

Fingerprint

interferon alfa-2b
Ovarian Neoplasms
Antigens
Neoplasm Antigens

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Recombinant alpha-2b-interferon dynamic test as a potential tool in predicting disease status during second look in ovarian cancer : A preliminary report. / Scambia, G.; Panici, P. B.; Baiocchi, G.; Gallo, A.; Laurelli, G.; Iacobelli, S.; Mancuso, S.

In: Cancer, Vol. 68, No. 12, 1991, p. 2582-2585.

Research output: Contribution to journalArticle

Scambia, G, Panici, PB, Baiocchi, G, Gallo, A, Laurelli, G, Iacobelli, S & Mancuso, S 1991, 'Recombinant alpha-2b-interferon dynamic test as a potential tool in predicting disease status during second look in ovarian cancer: A preliminary report', Cancer, vol. 68, no. 12, pp. 2582-2585.
Scambia, G. ; Panici, P. B. ; Baiocchi, G. ; Gallo, A. ; Laurelli, G. ; Iacobelli, S. ; Mancuso, S. / Recombinant alpha-2b-interferon dynamic test as a potential tool in predicting disease status during second look in ovarian cancer : A preliminary report. In: Cancer. 1991 ; Vol. 68, No. 12. pp. 2582-2585.
@article{74f2bd0a16784ceaa8e23a0cad430cba,
title = "Recombinant alpha-2b-interferon dynamic test as a potential tool in predicting disease status during second look in ovarian cancer: A preliminary report",
abstract = "The circulating levels of a 90-kilodalton (KD) tumor-associated antigen were measured in the blood of 26 patients with ovarian cancer in clinical remission who received a short course of recombinant alpha-2b-interferon (rIFN-alpha-2b, 3 million U/m2/d intramuscularly for 3 days) before second- look procedures. The administration of rIFN-alpha-2b to 90-KD antigen- positive patients produced a slight increase of the marker. However, in patients without the marker but with evidence of disease, a remarkable increase above the cutoff level was observed. Less pronounced modifications of 90-KD antigen serum levels were found in patients with no disease at second look. Moreover, considering the 90-KD antigen mean percentage increase, the dynamic test with rIFN-alpha-2b was able to eliminate five of six false-negative results obtained with the 90-KD antigen basal assay alone. The sensitivity of the assay increased to 92{\%} after IFN compared with 54{\%} for the 90-KD antigen assay alone. An increase (> 100{\%} above pretreatment titer) of 90-KD antigen levels during the test also was observed in four patients with no evidence of disease at second look. In two of these false-positive cases, recurrence of disease was observed 13 and 24 months later. At the time of this analysis, none of the patients with a negative second look and negative dynamic test had relapsed. These results suggest that the dynamic test with rIFN-alpha-2b might be a new tool to assess disease status in patients with ovarian cancer before second-look procedures.",
author = "G. Scambia and Panici, {P. B.} and G. Baiocchi and A. Gallo and G. Laurelli and S. Iacobelli and S. Mancuso",
year = "1991",
language = "English",
volume = "68",
pages = "2582--2585",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Recombinant alpha-2b-interferon dynamic test as a potential tool in predicting disease status during second look in ovarian cancer

T2 - A preliminary report

AU - Scambia, G.

AU - Panici, P. B.

AU - Baiocchi, G.

AU - Gallo, A.

AU - Laurelli, G.

AU - Iacobelli, S.

AU - Mancuso, S.

PY - 1991

Y1 - 1991

N2 - The circulating levels of a 90-kilodalton (KD) tumor-associated antigen were measured in the blood of 26 patients with ovarian cancer in clinical remission who received a short course of recombinant alpha-2b-interferon (rIFN-alpha-2b, 3 million U/m2/d intramuscularly for 3 days) before second- look procedures. The administration of rIFN-alpha-2b to 90-KD antigen- positive patients produced a slight increase of the marker. However, in patients without the marker but with evidence of disease, a remarkable increase above the cutoff level was observed. Less pronounced modifications of 90-KD antigen serum levels were found in patients with no disease at second look. Moreover, considering the 90-KD antigen mean percentage increase, the dynamic test with rIFN-alpha-2b was able to eliminate five of six false-negative results obtained with the 90-KD antigen basal assay alone. The sensitivity of the assay increased to 92% after IFN compared with 54% for the 90-KD antigen assay alone. An increase (> 100% above pretreatment titer) of 90-KD antigen levels during the test also was observed in four patients with no evidence of disease at second look. In two of these false-positive cases, recurrence of disease was observed 13 and 24 months later. At the time of this analysis, none of the patients with a negative second look and negative dynamic test had relapsed. These results suggest that the dynamic test with rIFN-alpha-2b might be a new tool to assess disease status in patients with ovarian cancer before second-look procedures.

AB - The circulating levels of a 90-kilodalton (KD) tumor-associated antigen were measured in the blood of 26 patients with ovarian cancer in clinical remission who received a short course of recombinant alpha-2b-interferon (rIFN-alpha-2b, 3 million U/m2/d intramuscularly for 3 days) before second- look procedures. The administration of rIFN-alpha-2b to 90-KD antigen- positive patients produced a slight increase of the marker. However, in patients without the marker but with evidence of disease, a remarkable increase above the cutoff level was observed. Less pronounced modifications of 90-KD antigen serum levels were found in patients with no disease at second look. Moreover, considering the 90-KD antigen mean percentage increase, the dynamic test with rIFN-alpha-2b was able to eliminate five of six false-negative results obtained with the 90-KD antigen basal assay alone. The sensitivity of the assay increased to 92% after IFN compared with 54% for the 90-KD antigen assay alone. An increase (> 100% above pretreatment titer) of 90-KD antigen levels during the test also was observed in four patients with no evidence of disease at second look. In two of these false-positive cases, recurrence of disease was observed 13 and 24 months later. At the time of this analysis, none of the patients with a negative second look and negative dynamic test had relapsed. These results suggest that the dynamic test with rIFN-alpha-2b might be a new tool to assess disease status in patients with ovarian cancer before second-look procedures.

UR - http://www.scopus.com/inward/record.url?scp=0025750831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025750831&partnerID=8YFLogxK

M3 - Article

C2 - 1933806

AN - SCOPUS:0025750831

VL - 68

SP - 2582

EP - 2585

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -